Navigation Links
Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research

GENEVA and RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented an update to the World Health Organization (WHO) on the development of the company's lead antiviral compound, CMX001, at the 12th Meeting of the WHO Advisory Committee on Variola Virus Research in a presentation titled "Status of CMX001 for Smallpox and Other dsDNA Viruses."  CMX001 is being developed for dual-use as a medical countermeasure in the event of a smallpox release and as a broad-spectrum antiviral for the treatment of life-threatening viruses in immunocompromised transplant and cancer patients.

"Chimerix is passionate about the need to develop effective antiviral therapeutics to improve global health and protect against viral threats such as smallpox.  Therefore, we are pleased by the opportunity to provide an update to the World Health Organization on the significant progress being made in the development of CMX001 as a potential dual-use agent," commented Wendy Painter, M.D., M.P.H., Chief Medical Officer of Chimerix.  "In addition to proven efficacy in numerous animal studies against pox viruses, we are amassing a significant body of clinical data in critically-ill patients regarding CMX001's safety and antiviral activity against double-stranded DNA viruses."

CMX001 is currently in Phase 2 clinical trials for prophylaxis of human cytomegalovirus infection and under development using the FDA's "Animal Rule" for smallpox infection.  It has proven effective in reduction of morbidity and mortality in animal models of smallpox, even when treatment is initiated after the onset of lesions.

CMX001 has a number of advantages over other drugs in development for treatment of smallpox, including: broad-spectrum inhibition of double-stranded DNA (dsDNA) viruses that cause human disease; a high barrier to resistance; convenient oral administration as a tablet or liquid; and no evidence to date of renal toxicity.  Uniquely among potential smallpox therapeutics, CMX001's safety and efficacy may be evaluated in patients with life-threatening dsDNA virus infections which share many basic traits with variola virus.  Further, CMX001 may be effective in the treatment of and protection against smallpox among the estimated 80-90 million Americans whose immune systems are compromised, such as those under treatment for cancer and many chronic diseases or people living with HIV.

About Chimerix and CMX001

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.

The company's lead candidate, CMX001, is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of life-threatening viruses, including cytomegalovirus and adenovirus.  Over 300 people have received CMX001 to date.  CMX001 has been well tolerated in all studies, with a growing body of evidence of the compound's antiviral activity in humans.  In Chimerix's ongoing placebo-controlled studies, CMX001 has been administered to more than 200 patients and healthy volunteers.  In addition, at the request of leading physicians at over 45 medical centers throughout the United States, Canada, Europe and Israel, CMX001 has been administered to more than 120 patients under investigator-held Emergency Investigational New Drug applications (EINDs) for the treatment of a wide range of infections caused by dsDNA viruses for which there are either no approved treatments or where patients have failed the available treatment.  To date, CMX001 has been used to treat patients with 12 different dsDNA viral infections across all five families of dsDNA viruses that affect humans. CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant funding from the National Institutes of Allergy and Infectious Disease to develop CMX001 for smallpox.

Chimerix's second clinical-stage antiviral compound, CMX157, has completed Phase 1 clinical studies.  CMX157 is in development as a potent nucleoside analogue against multi-drug resistant HIV infections.

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, malaria and other global public health needs.  For additional information on Chimerix, please visit

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
2. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
3. Chimerix to Present at Upcoming Investor Conferences
4. Chimerix Initiates Phase 1 Study of CMX157
5. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
6. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
7. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
8. Chimerix Joins International Network of Organizations to Cure Malaria
9. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
10. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
11. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions ... Melanie Aregger to serve as Chief Operating Officer. , Having joined InSphero ... team and was promoted to Head of InSphero Diagnostics in 2014. There ...
(Date:11/24/2015)... QC , Nov. 24, 2015 /CNW Telbec/ - ProMetic ... "Corporation") announced today that Mr. Pierre Laurin , President ... corporate presentation at the upcoming Piper Jaffray 27 th ... Palace Hotel, on December 1-2, 2015. st ... available for one-on-one meetings throughout the day. The presentation will ...
(Date:11/24/2015)... Nov. 24, 2015 HemoShear Therapeutics, LLC, ... drugs for metabolic disorders, announced today the appointment ... Board of Directors (BOD). Mr. Watkins is the ... Genome Sciences (HGS), and also served as the ... Jim Powers , Chairman and CEO of HemoShear ...
(Date:11/24/2015)... NEW YORK , November 24, 2015 /PRNewswire/ ... Bristol-Myers Squibb in a European ... Company in which the companies will work closely together ... other areas of unmet medical need. The collaboration is underpinned ... the latest LSP fund. This is the first investment by ...
Breaking Biology Technology:
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
(Date:10/26/2015)... and LAS VEGAS , ... Nok Labs , an innovator in modern authentication and ... today announced the launch of its latest version of ... platform enabling organizations to use standards-based authentication that supports ... Nok S3 Authentication Suite is ideal for organizations deploying ...
Breaking Biology News(10 mins):